RESEARCH SAVES LIVES
Because of medical research, improvements have been made in early detection and treatment of breast cancer, leading to a 40% decrease in mortality in the U.S. over the past 30 years. There are more than 3.8 million breast cancer survivors in the U.S. today. Despite this tremendous progress, nearly 44,000 breast cancer deaths are predicted for this year in the U.S. alone. Komen’s mission is to address the most critical needs of our communities and to continue to invest in scientific research that will ultimately end breast cancer forever.

By listening to our patient advocates and working with our scientific advisors, we are setting research priorities that are helping us achieve our mission. These priorities include working together to conquer metastatic breast cancer (MBC), eliminating disparities in breast cancer outcomes and putting Big Data to work for breast cancer patients.

Our research investments are guided by more than 50 leading scientists and advocates, including our Scientific Advisory Board and Komen Scholars. We fund the brightest minds who are leading groundbreaking breast cancer research. Our research program is also patient-focused, with patient advocates involved in every step of our process.

As a global leader in the fight against breast cancer, we have funded research in 47 states and the District of Columbia, and 24 different countries. Our commitment to supporting the most promising, innovative and meaningful breast cancer research will never waver.

Visit the Fast Facts series to learn more about our research investment on a particular topic.

OUR RESEARCH INVESTMENT:
Nearly $1.1 billion in more than 2,700 research grants and more than 530 clinical trials

What are Komen-funded researchers doing right now?
• Testing MBC samples from people treated with a targeted therapy linked to a cancer cell-killing drug to discover ways to prevent drug resistance.
• Evaluating a novel health care navigation intervention designed to facilitate chemotherapy initiation and completion in underserved populations with breast cancer.
• Using artificial intelligence to analyze large, complex datasets to identify biomarkers that will optimize current and future personalized medicine strategies for people with breast cancer.

Research Discoveries in the Pipeline
More than 3,000 new breast cancer research products (drugs, biomarkers, devices, etc.).
Over 650 new discoveries focused on metastatic breast cancer.
More than 1,200 potential treatments, more than 400 focused on metastatic breast cancer.
Nearly 400 new strategies to reduce breast cancer disparities.

Visit the Fast Facts series to learn more about our research investment on a particular topic.

Survivorship & Outcomes research focuses on a broad range of areas including management of side effects; support, education and communication strategies for patients, family/caregivers and health care professionals; and health care delivery approaches to improve quality of life.

*Survivorship & Outcomes research focuses on a broad range of areas including management of side effects; support, education and communication strategies for patients, family/caregivers and health care professionals; and health care delivery approaches to improve quality of life.

Research Program Overview

Learn More About Breast Cancer
Learn More About Komen-funded Research
Get Involved & Support Komen Research

©2022 Susan G. Komen®. July 2022